metaEvidence - study list


	Study	study type RCT OBS RCT + OBS	Pathology	T1	T0	Patients	sample sizes	ROB	Results	deaths (OS) E	progression or deaths (PFS) E	RFS/DFS E
metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)
versus sunitinib
	nivolumab plus ipilimumab
	CheckMate 214 (all population), 2017 Lancet Oncol. 2019; 20:1370-1385 N. Engl. J. Med. 2018; 378:1277-1290 Urologe A 2015; 54:1443-5 J Immunother Cancer 2020 Jul;8(2):e000891. Jpn J Clin Oncol 2020 Jan 24;50(1):12-19. Clin Cancer Res 2020 Sep 1. NCT02231749	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	nivolumab plus ipilimumab	sunitinib	patients previously untreated advanced or metastatic renal cell carcinoma with a clear-cell component	550 / 546	some concern	inconclusive
	CheckMate 214 (intermediate and poor risk), 2017 Lancet Oncol. 2019; 20:1370-1385 N. Engl. J. Med. 2018; 378:1277-1290 J Immunother Cancer 2020 Jul;8(2):e000891. Jpn J Clin Oncol 2020 Jan 24;50(1):12-19. Immunotherapy 2020 Jan;12(1):37-51. Lancet Oncol 2019 Feb;20(2):297-310. Eur Urol 2022; 81:266-271-. Cancer 2022; 128:2085-2097-. NCT02231749	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	nivolumab plus ipilimumab	sunitinib	patients previously untreated advanced or metastatic renal cell carcinoma with a clear-cell component	425 / 422	some concern	conclusif
	CheckMate 214 (favorable risk) EXPLORATORY, 2017 Lancet Oncol. 2019; 20:1370-1385 N. Engl. J. Med. 2018; 378:1277-1290 J Immunother Cancer 2020 Jul;8(2):e000891. Jpn J Clin Oncol 2020 Jan 24;50(1):12-19. Immunotherapy 2020 Jan;12(1):37-51. Lancet Oncol 2019 Feb;20(2):297-310. NCT02231749	RCT	metastatic/advanced RCC (mRCC) - 1st line (L1)	nivolumab plus ipilimumab	sunitinib	patients previously untreated advanced or metastatic renal cell carcinoma with a clear-cell component, with favorable risk (IMDCC)	125 / 124	some concern	inconclusive

metastatic/advanced RCC (mRCC) - 1st line (L1) metastatic/advanced RCC (mRCC) - 1st line (L1)

versus sunitinib

nivolumab plus ipilimumab